A detailed history of Jpmorgan Chase & CO transactions in Olema Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 181,032 shares of OLMA stock, worth $1.59 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
181,032
Previous 23,861 658.69%
Holding current value
$1.59 Million
Previous $258,000 737.6%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$10.41 - $16.46 $1.64 Million - $2.59 Million
157,171 Added 658.69%
181,032 $2.16 Million
Q2 2024

Aug 12, 2024

BUY
$8.73 - $13.99 $8,520 - $13,654
976 Added 4.26%
23,861 $258,000
Q1 2024

May 10, 2024

SELL
$10.95 - $16.62 $62,316 - $94,584
-5,691 Reduced 19.92%
22,885 $259,000
Q4 2023

Feb 12, 2024

BUY
$10.53 - $17.14 $107,437 - $174,879
10,203 Added 55.53%
28,576 $400,000
Q3 2023

Nov 14, 2023

SELL
$8.19 - $12.98 $21,261 - $33,696
-2,596 Reduced 12.38%
18,373 $226,000
Q2 2023

Aug 11, 2023

BUY
$3.22 - $9.65 $63,675 - $190,828
19,775 Added 1656.2%
20,969 $189,000
Q4 2022

Feb 13, 2023

SELL
$2.27 - $3.76 $638,053 - $1.06 Million
-281,081 Reduced 99.58%
1,194 $3,000
Q3 2022

Nov 14, 2022

BUY
$2.72 - $5.88 $3,519 - $7,608
1,294 Added 0.46%
282,275 $779,000
Q2 2022

Aug 11, 2022

BUY
$2.04 - $4.61 $514,449 - $1.16 Million
252,181 Added 875.63%
280,981 $1.14 Million
Q1 2022

May 11, 2022

BUY
$3.89 - $9.43 $19,169 - $46,471
4,928 Added 20.64%
28,800 $122,000
Q4 2021

Feb 10, 2022

BUY
$8.75 - $30.71 $55,597 - $195,131
6,354 Added 36.27%
23,872 $224,000
Q3 2021

Nov 12, 2021

BUY
$22.96 - $30.13 $402,213 - $527,817
17,518 New
17,518 $483,000

Others Institutions Holding OLMA

About Olema Pharmaceuticals, Inc.


  • Ticker OLMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,419,600
  • Market Cap $355M
  • Description
  • Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...
More about OLMA
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.